Clinical Trials
8 trialsNCT06871410 2026-03-24
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT06199557 2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2 Recruiting
NCT02626715 2024-07-16
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
Phase 2 Completed
NCT02088541 2023-01-26
SOPRA
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT00005823 2013-12-18
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 3 Completed
NCT00083187 2013-07-18
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
National Cancer Institute (NCI)
Phase 2 Completed